Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6979910 | 0.83 | NAMPT (0.56) | NAMPTALDH1A1POLBHTTL3MBTL1 | |
| SCHEMBL14369280 | 0.83 | HTT (0.51) | NAMPTALDH1A1POLBHTTL3MBTL1 | |
| Cp1-1189 SCHEMBL154117 | 0.83 | CACNA1B (0.61) | CACNA1BAPBA1EPHX2NR1H4ALDH1A1 | |
| SCHEMBL28795018 | 0.80 | CACNA1B (0.50) | CACNA1BAPBA1EPHX2NR1H4ALDH1A1 | |
| SCHEMBL19592503 | 0.80 | HTT (0.54) | NAMPTALDH1A1POLBCYP3A4BLM | |
| Cp1-1189 SCHEMBL7379007 | 0.79 | CACNA1B (0.56) | CACNA1BAPBA1EPHX2NR1H4ALDH1A1 | |
| SCHEMBL20193359 | 0.78 | HTT (0.52) | NAMPTALDH1A1POLBHTTL3MBTL1 | |
| SCHEMBL25767472 | 0.78 | HTT (0.52) | NAMPTEPHX2NR1H4ALDH1A1SMN1; SMN2 | |
| SCHEMBL5940572 | 0.78 | HTT (0.52) | NAMPTEPHX2ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL25780577 | 0.78 | KDM4E (0.61) | NAMPTALDH1A1POLBHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004060286-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | RENOVIS, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-6759433-B2 | FOR THERAPY OF PARKINSON'S DISEASE | RENOVIS, INC. | 2004-07-06 | — | — | US | claimed |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2003-09-18 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| US-6509378-B2 | Parkinson's disease; ability to antagonize MPTP induced reduction in dopamine levels; amidation of the nitrobenzoyl halide with alkylamine | CENTAUR PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2001-11-01 | — | — | US | claimed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1079820-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | claimed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| WO-1999059569-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| US-5955506-A | ACETAMIDOBENZAMIDE COMPOUNDS FOR TREATMENT OF PARKINSON'S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | disclosed |
| EP-0542363-A2 | Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation | GLAXO GROUP LIMITED (GB) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | NAMPT 1329/4885CACNA1B 1087/4885APBA1 29/4885 |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | NAMPT 1329/4885CACNA1B 1087/4885APBA1 29/4885 |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | NAMPT 2068/4885CACNA1B 191/4885APBA1 529/4885 |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | NAMPT 1329/4885CACNA1B 1087/4885APBA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.